Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT03842904 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Study Comparing the Effects of Trimbow to Fostair in COPD

TRIFLOW
Start date: December 13, 2018
Phase: Phase 4
Study type: Interventional

A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation in moderate to severe chronic obstructive pulmonary disease (COPD).

NCT ID: NCT03836677 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

Start date: February 15, 2019
Phase: Phase 3
Study type: Interventional

This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway dimensions.

NCT ID: NCT03836547 Enrolling by invitation - COPD Clinical Trials

Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Researchers are trying to see if a multicomponent intervention to support weight loss decreases dyspnea in obese people with lung disease.

NCT ID: NCT03828630 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients

LUSIP
Start date: July 8, 2018
Phase:
Study type: Observational

This study aims at describing the frequency, timing and type of pulmonary complications detected with lung ultrasound in critically-ill parturients in admitted to a high-dependency unit in Freetown, Sierra Leone.

NCT ID: NCT03824834 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness

MorEx
Start date: March 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the role of low-dose immediate-release oral morphine as a novel adjunct pharmacotherapy to enable symptomatic adults with advanced chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) to exercise at higher intensities for longer durations and maximize the psycho-physiological benefits of a supervised exercise training program. We hypothesize that, compared to placebo, exercise training with oral morphine will result in relatively greater improvements in exercise endurance time and intensity ratings of perceived breathlessness during constant-load cardiopulmonary cycle exercise testing (CPET) at 75% of peak power output (PPO).

NCT ID: NCT03823443 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

COPD Exacerbation Blood and Urine Biomarkers Study

Start date: June 7, 2018
Phase:
Study type: Observational

This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.

NCT ID: NCT03821311 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Investigating the Effect of Nasal High Flow Oxygen Therapy on Regional Lung Function

INVENT
Start date: December 6, 2018
Phase: N/A
Study type: Interventional

This study aims to assess the effect of nasal high flow oxygen therapy on regional function measured by volumetric computed tomography, in patients with chronic obstructive pulmonary disease.

NCT ID: NCT03821285 Recruiting - Clinical trials for Lung Diseases, Obstructive

Respiratory Function in Patients With Post-tuberculosis Lung Impairment

Start date: February 14, 2019
Phase: N/A
Study type: Interventional

Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due to residual lung damage. A recent review of the literature on TB sequelae and rehabilitation has provided clear evidence that TB is definitively responsible for lung function impairment. Functional evaluation of TB patients after completion of pulmonary tuberculosis treatment or spontaneous healing should be considered as part of clinical care. Unfortunately, few studies are available in the literature investigating the physiopathology of lung damage, its impact on quality of life, the potential need for pulmonary rehabilitation (PR), and the effects of a PR program.Objectives of this prospective multicentre international study are: Primary Objective-to assess the exercise capacity 6-min walking test in patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment or after spontaneous healing. Secondary Objectives-to assess the effects of the PR program on dyspnoea symptoms and muscle fatigue, quality of life.

NCT ID: NCT03820726 Not yet recruiting - Clinical trials for Lung Diseases, Interstitial

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Start date: April 15, 2019
Phase: Phase 3
Study type: Interventional

The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).

NCT ID: NCT03819517 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

Start date: February 2019
Phase: N/A
Study type: Interventional

Researchers have found a link between chronic obstructive pulmonary disease (COPD) and heart disease; however, a link is all they have found. Cardiovascular health in COPD is controlled by different mechanisms including vascular health and systemic inflammation. The investigators have collected preliminary data to support that concentrations of Sirtuin 1 (Sirt1), a protein that plays a key role in cardioprotection, may be involved in cardiovascular health in patients with COPD. Resveratrol, an over the counter natural polyphenol found in a variety of food, is a direct activator of Sirt1 and has been used to improve cardiovascular health in different cohorts. The current project is an attempt to expand previous findings and explore the effects of the sub-chronic use of resveratrol in sustaining the improvements in cardiovascular health in COPD.